Company news

Xencor, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Xencor Reports First Quarter 2021 Financial Results

May 4, 2021

Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021

April 27, 2021

Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases

April 27, 2021

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021

April 9, 2021

Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021

March 9, 2021

Xencor to Present at the Barclays Global Healthcare Conference

March 2, 2021

Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics

February 24, 2021

Xencor Reports Fourth Quarter and Full Year 2020 Financial Results

February 22, 2021

Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021

February 15, 2021

Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer

January 5, 2021

Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer

December 6, 2020

Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting

December 5, 2020

Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

November 10, 2020

Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

November 8, 2020

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting

November 8, 2020

Xencor Reports Third Quarter 2020 Financial Results

November 4, 2020

Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting

November 3, 2020

Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020

October 28, 2020

Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting

October 13, 2020

Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium

October 1, 2020

Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium

September 8, 2020

Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

September 8, 2020

Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates

September 2, 2020

Xencor Reports Second Quarter 2020 Financial Results

August 3, 2020

Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States

July 30, 2020

Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020

July 27, 2020

Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

July 7, 2020

Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

July 7, 2020

Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

June 21, 2020

Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

May 14, 2020

Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

May 12, 2020

Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors

May 12, 2020

Xencor Reports First Quarter 2020 Financial Results

May 6, 2020

Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020

April 29, 2020

Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19

March 24, 2020

Xencor Reports Fourth Quarter and Full Year 2019 Financial Results

February 23, 2020

Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020

February 17, 2020

Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV

January 7, 2020

Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors

December 19, 2019

Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer

December 17, 2019

Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting

December 8, 2019

Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting

November 5, 2019

Xencor Reports Third Quarter 2019 Financial Results

November 4, 2019

Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019

October 28, 2019

Xencor to Present at the 2019 Cantor Global Healthcare Conference

September 25, 2019

Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary

September 9, 2019

← Newer news releases

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.